Skip to Content
Merck
All Photos(1)

Key Documents

AB1056F

Sigma-Aldrich

Anti-Adenovirus Antibody, FITC-conjugated

Chemicon®, from goat

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

goat

Quality Level

conjugate

FITC conjugate

antibody form

purified antibody

antibody product type

primary antibodies

clone

polyclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunofluorescence: suitable
immunohistochemistry: suitable

shipped in

wet ice

Specificity

Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells

Immunogen

Hexon from adenovirus type 5.

Application

Anti-Adenovirus Antibody, FITC-conjugated is an antibody against Adenovirus for use in IF, IH.
Direct FA staining of target antigens in a permissive tissue culture system. Suggested dilution: 1:10-1:50. Acetone fixation of the antigen source is recommended prior to staining.

Optimal working dilutions must be determined by end user
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

Physical form

IgG fraction conjugated to FITC. In PBS (0.01 M, pH 7.2) containing 10 mg/mL BSA and 0.1% sodium azide

Storage and Stability

Maintain at 2-8°C for 3 months or at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. Store under subdued light.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

In situ adenovirus vaccination engages T effector cells against cancer.
Sebastian Tuve, Ying Liu, Khajornsak Tragoolpua, Jeffrey Daniel Jacobs et al.
Vaccine null
Comparison of adenoviruses from species B, C, E, and F after intravenous delivery.
Daniel Stone, Ying Liu, Zong-Yi Li, Sebastian Tuve, Robert Strauss, Andre Lieber
Molecular Therapy null
Sacha Robert et al.
Viruses, 16(4) (2024-04-27)
Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically
Yoshihiko Kakiuchi et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(10), 2920-2930 (2021-05-24)
Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301)
Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration.
F A Nunes, E E Furth, J M Wilson, S E Raper
Human Gene Therapy null

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service